451 related articles for article (PubMed ID: 30690602)
41. Pulmonary Coccidioidomycosis: A Case Report and Literature Review.
Alčauskas T; Zablockienė B; Zablockis R; Svetikas L; Bilotaitė L; Jančorienė L
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630071
[TBL] [Abstract][Full Text] [Related]
42. CARD9-Associated Dectin-1 and Dectin-2 Are Required for Protective Immunity of a Multivalent Vaccine against
Campuzano A; Zhang H; Ostroff GR; Dos Santos Dias L; Wüthrich M; Klein BS; Yu JJ; Lara HH; Lopez-Ribot JL; Hung CY
J Immunol; 2020 Jun; 204(12):3296-3306. PubMed ID: 32358020
[No Abstract] [Full Text] [Related]
43. Pathology of coccidioidomycosis in llamas and alpacas.
Fernandez JA; Hidalgo MN; Hodzic E; Diab SS; Uzal FA
J Vet Diagn Invest; 2018 Jul; 30(4):560-564. PubMed ID: 29790449
[TBL] [Abstract][Full Text] [Related]
44. Coccidioides species antifungal susceptibility testing: Experience from a large healthcare system in the endemic region.
Zangeneh TT; Lainhart WD; Wiederhold NP; Al-Obaidi MM
Med Mycol; 2023 Oct; 61(10):. PubMed ID: 37804176
[TBL] [Abstract][Full Text] [Related]
45. Risk factors and outcomes of culture-proven acute Coccidioides spp. infection in San Diego, California, United States.
Jenks JD; Reed SL; Hoenigl M
Mycoses; 2020 Jun; 63(6):553-557. PubMed ID: 32176829
[TBL] [Abstract][Full Text] [Related]
46. The mysterious desert dwellers: Coccidioides immitis and Coccidioides posadasii, causative fungal agents of coccidioidomycosis.
Kollath DR; Miller KJ; Barker BM
Virulence; 2019 Dec; 10(1):222-233. PubMed ID: 30898028
[TBL] [Abstract][Full Text] [Related]
47. PM10 and Other Climatic Variables Are Important Predictors of Seasonal Variability of Coccidioidomycosis in Arizona.
Kollath DR; Mihaljevic JR; Barker BM
Microbiol Spectr; 2022 Apr; 10(2):e0148321. PubMed ID: 35319247
[TBL] [Abstract][Full Text] [Related]
48. Epidemiology, Clinical Features, and Outcomes of Coccidioidomycosis, Utah, 2006-2015.
Carey A; Gorris ME; Chiller T; Jackson B; Beadles W; Webb BJ
Emerg Infect Dis; 2021 Sep; 27(9):2269-2277. PubMed ID: 34423764
[TBL] [Abstract][Full Text] [Related]
49. FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.
O'Shaughnessy E; Yasinskaya Y; Dixon C; Higgins K; Moore J; Reynolds K; Ampel NM; Angulo D; Blair JE; Catanzaro A; Galgiani JN; Garvey E; Johnson R; Larwood DJ; Lewis G; Purdie R; Rex JH; Shubitz LF; Stevens DA; Page SJ; Shukla SJ; Farley JJ; Nambiar S
Clin Infect Dis; 2022 Jun; 74(11):2061-2066. PubMed ID: 34651656
[TBL] [Abstract][Full Text] [Related]
50. The Quest for a Vaccine Against Coccidioidomycosis: A Neglected Disease of the Americas.
Kirkland TN
J Fungi (Basel); 2016 Dec; 2(4):. PubMed ID: 29376949
[TBL] [Abstract][Full Text] [Related]
51. Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate.
Orsborn KI; Shubitz LF; Peng T; Kellner EM; Orbach MJ; Haynes PA; Galgiani JN
Infect Immun; 2006 Mar; 74(3):1865-72. PubMed ID: 16495561
[TBL] [Abstract][Full Text] [Related]
52. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species.
Blair JE
Curr Opin Infect Dis; 2008 Aug; 21(4):415-20. PubMed ID: 18594295
[TBL] [Abstract][Full Text] [Related]
53. Early treatment with fluconazole may abrogate the development of IgG antibodies in coccidioidomycosis.
Thompson GR; Lunetta JM; Johnson SM; Taylor S; Bays D; Cohen SH; Pappagianis D
Clin Infect Dis; 2011 Sep; 53(6):e20-4. PubMed ID: 21865185
[TBL] [Abstract][Full Text] [Related]
54. Coccidioidomycosis of the spine in an immunocompetent patient.
Reach P; Paugam A; Kahan A; Allanore Y; Wipff J
Joint Bone Spine; 2010 Dec; 77(6):611-3. PubMed ID: 20554239
[TBL] [Abstract][Full Text] [Related]
55. Valley fever: danger lurking in a dust cloud.
Johnson L; Gaab EM; Sanchez J; Bui PQ; Nobile CJ; Hoyer KK; Peterson MW; Ojcius DM
Microbes Infect; 2014 Aug; 16(8):591-600. PubMed ID: 25038397
[TBL] [Abstract][Full Text] [Related]
56. Coccidioidal Hepatic Abscess in a Patient With Disseminated Coccidioidomycosis: A Case Report.
Raza N; Nasrawi F; Heidari A; Kuran R; Amin N; Johnson R
J Investig Med High Impact Case Rep; 2021; 9():23247096211033051. PubMed ID: 34311612
[TBL] [Abstract][Full Text] [Related]
57. Molecular and cellular mechanisms of protective immunity to coccidioidomycosis.
Kirkland TN; Raz E; Datta SK
Vaccine; 2006 Jan; 24(4):495-500. PubMed ID: 16181709
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of two homologous proline-rich proteins of Coccidioides posadasii as candidate vaccines against coccidioidomycosis.
Herr RA; Hung CY; Cole GT
Infect Immun; 2007 Dec; 75(12):5777-87. PubMed ID: 17875631
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group.
Pappagianis D
Am Rev Respir Dis; 1993 Sep; 148(3):656-60. PubMed ID: 8368636
[TBL] [Abstract][Full Text] [Related]
60. Coccidioidomycosis: first cases reported in Pernambuco, Brazil.
Araújo PSR; Souza Junior VR; Padilha CE; Oliveira MI; Arraes LC; Vieira R; Antunes A; Lima Neto RG; Marsden A
Rev Inst Med Trop Sao Paulo; 2018 Nov; 60():e75. PubMed ID: 30462798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
